Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Salarius Pharmaceuticals Inc SLRX

Healthcare Biotechnology
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and... see more

Recent & Breaking News (NDAQ:SLRX)

Salarius Pharmaceuticals Announces Titles of Three Abstracts Accepted for Poster Presentations at American Society of Clinical Oncology 2021 Annual Meeting

GlobeNewswire April 29, 2021

Salarius Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentations at the 2021 American Society of Clinical Oncology Annual Meeting

GlobeNewswire April 19, 2021

Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2020 Financial Results

GlobeNewswire March 18, 2021

Salarius Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire March 11, 2021

Salarius Announces Closing of $23 Million Underwritten Public Offering of Common Stock Following Full Exercise of Over-Allotment Option

GlobeNewswire March 8, 2021

Salarius Announces Pricing of $20 Million Underwritten Public Offering of Common Stock

GlobeNewswire March 4, 2021

Salarius Announces Proposed Public Offering of Common Stock

GlobeNewswire March 3, 2021

Salarius Pharmaceuticals Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas

GlobeNewswire February 24, 2021

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Virtual Conference

GlobeNewswire February 22, 2021

Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

GlobeNewswire February 17, 2021

Salarius Pharmaceuticals to Present at BIO CEO & Investor Digital Conference

GlobeNewswire February 16, 2021

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

GlobeNewswire January 21, 2021

Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference

GlobeNewswire January 15, 2021

Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas

GlobeNewswire January 13, 2021

Salarius Pharmaceuticals to Participate in Biotech Showcase Digital and BIO @ JPM During "J.P. Morgan Week 2021"

GlobeNewswire December 22, 2020

Salarius Announces Exercise Of Warrants For $3.5 Million Of Gross Proceeds To Be Used For Ongoing Development Of Seclidemstat

GlobeNewswire December 11, 2020

Salarius Pharmaceuticals Receives First Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas

GlobeNewswire December 10, 2020

Salarius Pharmaceuticals to Participate in A.G.P.'s Virtual Healthcare Symposium

GlobeNewswire November 17, 2020

Salarius Pharmaceuticals Reports Business Highlights and Third Quarter 2020 Financial Results

GlobeNewswire November 11, 2020

Salarius Pharmaceuticals to Report Third Quarter 2020 Financial Results

GlobeNewswire November 4, 2020